8-dihalogenomethylene dihydroberberine type compound and its anti-infection and anti-inflammation application

A technology of dihalomethylenedihydroberberine and methylenedioxy is applied in the application field of preparing anti-microbial infection and anti-inflammatory products, and can solve the problems affecting pharmacological effects, structural changes, and chemical structure instability. and other problems, to achieve significant medicinal efficacy and safety, and the application prospect is significant.

Active Publication Date: 2021-08-13
INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Published data show that derivatives of various parent unsubstituted dihydroberberine structures and derivatives of dihydroberberine structures substituted with an acetonyl group at the 8-position have clear and significant anti-ulcerative colitis activity , but there is an unstable chemical structure, and structural changes are likely to occur in a variety of solvents, thus affecting pharmacological effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 8-dihalogenomethylene dihydroberberine type compound and its anti-infection and anti-inflammation application
  • 8-dihalogenomethylene dihydroberberine type compound and its anti-infection and anti-inflammation application
  • 8-dihalogenomethylene dihydroberberine type compound and its anti-infection and anti-inflammation application

Examples

Experimental program
Comparison scheme
Effect test

experiment example (1

[0046] Experimental example (1) Preparation process and structural identification data of compound 1

[0047] Coptis alkaloid hydrochloride (2.0 g, 5.62 mmol) was dissolved in 200 mL of chloroform-methanol (3:1) mixed solvent in a reaction flask, 24 mL of concentrated ammonia water was added, and the reaction was stirred at room temperature for 24 h, and then the chloroform layer was separated, and The chloroform layer was washed twice with water, with anhydrous MgSO 4 After drying, filtration; the filtrate was evaporated to dryness, and the residual crude product obtained was purified by silica gel column chromatography, eluted with dichloromethane, and the eluate was concentrated to obtain 617 mg of 8-trichloromethyldihydrocoptidine as a pale yellow solid, yield 25.0%. 1 H NMR (500MHz, CDCl 3 )δ: 2.63–2.78 (m, 1H, NCH 2 C H 2 ),3.35(m,1H,NCH 2 C H 2 ),3.71(m,1H,NC H 2 CH 2 ),3.78-3.90(m,1H,NC H 2 CH 2 ),5.42(s,1H,CH-CCl 3 ),5.91(br,1H,OCH 2 O),5.95(br,2H,OCH ...

experiment example (2

[0048] Experimental example (2) Preparation process and structural identification data of compound 2

[0049] Dissolve isoplastin hydrochloride (1.0 g, 2.81 mmol) in 80 ml of chloroform in a reaction flask, add NaH (450 mg, 18.75 mmol) under ice, slowly warm up to room temperature and stir the reaction for 24 h, then concentrate the reaction solution under reduced pressure to A residue was obtained; ethyl acetate was added to the residue first, followed by an appropriate amount of purified water, extracted with ethyl acetate for 3 times, combined with the ethyl acetate extracts, and washed with anhydrous MgSO 4 Dry, filter, and evaporate the filtrate to dryness. The obtained crude product was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (3 / 1, v / v), and the eluate was concentrated to obtain 8-trichloromethyldihydrogen Isoptyxine yellow solid 995mg, yield 80.7%. 1 HNMR (500MHz, CDCl 3 )δ: 2.68(d, J=15.5Hz, 1H, NCH 2 C H 2 ),3.35-3....

experiment example (3

[0050] Experimental example (3) Preparation process and structural identification data of compound 3

[0051] Berberine hydrochloride (2.0 g, 5.38 mmol) was dissolved in 60 ml of chloroform in a reaction flask, 24 ml of concentrated ammonia water was added, and the reaction was stirred at room temperature for 24 h, then the chloroform layer was separated, and the chloroform solution was washed with water twice, with Anhydrous MgSO 4 The chloroform solution was dried and filtered, and the filtrate was evaporated to dryness to obtain a residue; the residue was separated and purified by silica gel column chromatography, eluted with dichloromethane, and the eluent was evaporated to dryness to obtain 8-trichloromethyldihydrobarberry Alkali pale yellow solid 1.775g, yield 78.9%. 1 H NMR (500MHz, CDCl 3 )δ: 2.73(d, J=15.5Hz, 1H, NCH 2 C H 2 ),3.33(m,1H,NCH 2 C H 2 ),3.71(m,1H,NC H 2 CH 2 ),3.87(ov,4H,ArOCH 3 ,NC H 2 CH 2 ),3.94(s,3H,ArOCH 3 ),5.65(s,1H,CH-CCl 3 ),5.9...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
control rateaaaaaaaaaa
Login to view more

Abstract

The invention discloses an 8-dihalogenomethylene dihydroberberine type compound and its anti-infection and anti-inflammation application, and specifically relates to an 8-dihalogenomethylene dihydroberberine type compound as shown in general formula I and Its physiologically acceptable salt, its synthesis method and its application in the preparation of products for preventing, alleviating and / or treating microbial infection and inflammation. Compared with the berberine type alkaloid quaternary ammonium salt substrate, the described 8-dihalogenated methylene dihydroberberine type compound shows significantly improved antibacterial activity to Gram-positive bacteria and fungi; Soybean oil-induced mouse ear acute swelling model animals show significant anti-inflammatory activity; the pharmacological action intensity of the compound of the present invention is obviously higher than that of the control drug, and has the advantages of no toxicity or low toxicity at the same time, and can be used for the preparation of prophylaxis, relief and and / or products for the treatment of microbial infections and inflammations.

Description

technical field [0001] The present invention relates to a class of 8-dihalomethylenedihydroberberine derivatives obtained by derivatization using various naturally occurring berberine quaternary ammonium salt compounds as substrates or physiologically acceptable The salt of the invention, its preparation method and use in the preparation of anti-microbial infection and anti-inflammatory products. It belongs to the field of medical technology. Background technique [0002] Antimicrobial (or antibacterial) infection drugs are the first class of drugs used clinically. There are many antibacterial drugs commonly used in clinical practice, including β-lactams, aminoglycosides, macrolides, quinolones and tetracyclines. However, due to the overuse of well-known antibacterial drugs, bacterial resistance has increased year by year, resulting in diseases such as methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant streptococcus ) and multidrug-resistant Mycobact...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D455/03A61K31/4375A61K8/49A61Q19/00A61P31/04A61P31/10A61P29/00A23L33/10
CPCA23V2002/00A61K8/4926A61Q19/00A23L33/10A61P29/00A61P31/04A61P31/10C07D455/03A23V2200/30A23V2250/30
Inventor 秦海林吴练秋李想张海婧宋利宋华琛张志辉唐晓楠邓安珺李志宏
Owner INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap